Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Gains from Sales and Divestitures: 2019-2025

  • Eton Pharmaceuticals' Gains from Sales and Divestitures fell 6.86% to $84,204 in Q3 2025 from the same period last year, while for Sep 2025 it was $84,204, marking a year-over-year decrease of 6.86%. This contributed to the annual value of $90,402 for FY2024, which is 1.09% down from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Gains from Sales and Divestitures of $84,204 as of Q3 2025, which was up 9,371.77% from $889 recorded in Q2 2025.
  • Eton Pharmaceuticals' Gains from Sales and Divestitures' 5-year high stood at $91,402 during Q3 2023, with a 5-year trough of $889 in Q2 2025.
  • In the last 3 years, Eton Pharmaceuticals' Gains from Sales and Divestitures had a median value of $90,402 in 2024 and averaged $74,784.
  • Data for Eton Pharmaceuticals' Gains from Sales and Divestitures shows a maximum YoY dropped of 6.86% (in 2025) over the last 5 years.
  • Quarterly analysis of 4 years shows Eton Pharmaceuticals' Gains from Sales and Divestitures stood at $7,595 in 2021, then reached $91,402 in 2023, then fell by 1.09% to $90,402 in 2024, then fell by 6.86% to $84,204 in 2025.
  • Its last three reported values are $84,204 in Q3 2025, $889 for Q2 2025, and $90,402 during Q4 2024.